Lymphoma Leukemia
Conditions
Keywords
CAR19-tTreg
Brief summary
This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL). The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.
Interventions
DRUGallogeneic CAR19 regulatory T cells (CAR19-tTreg)
A single dose administration of CAR19-tTreg
DRUGFludarabine
Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
DRUGCyclophosphamide
Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
Sponsors
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of R/R CD19+ B-ALL after failure of standard of care therapies with CD19 expression on blasts confirmed by flow cytometry or immunohistochemistry and meeting one or more of the following criteria: 1. Primary induction failure with no complete remission after ≥2 cycles of induction chemotherapy/immunotherapy, or 2. First relapse with no CR after 1 cycle of induction therapy, or 3. Second or greater relapse, or 4. Ph+ ALL and failure or intolerance to three lines of tyrosine kinase inhibitors (TKI) assuming one or more of the above criteria are also met. * Karnofsky performance status (KPS) ≥70% at screening * Adequate organ function is defined as: 1. Renal: Calculated estimated glomerular filtration rate greater than or equal to50 mL/min/1.73 m2 2. Hepatic: ALT and AST less than 3x upper limit of normal (ULN), and bilirubin less than2x ULN (exception, patients with Gilbert syndrome, total less than 3 x ULN and direct less than 1.5 x ULN) 3. Cardiac: Left ventricular ejection fraction (LVEF) greater than 45% by echocardiogram 4. Pulmonary: SpO2 greater than 92% on room air * Use of antiproliferative chemotherapy more than 2 weeks prior to enrollment and blinatumomab more than 4 weeks prior to enrollment * Patients with relapsed disease after prior allogeneic transplantation may be considered. In addition to the eligibility criteria otherwise listed, this subgroup must be more than 3 months from allogeneic hematopoietic stem cell transplant (HSCT), off immune suppressive therapy (e.g., calcineurin inhibitor, glucocorticoid, sirolimus) at least 4 weeks without GVHD. * Patients who received prior CAR-T therapy are eligible if more than 2 months after CAR-T infusion and CD19 expression is confirmed at the most recent relapse and all other criteria are met * Voluntary informed consent by the patient for treatment and follow-up for 15 years after treatment.
Exclusion criteria
* Availability of a FDA approved CAR T cell therapeutic targeting CD19+ B-ALL (patients eligible for but unable to receive FDA approved CAR T cells based on insurance limitations, may be eligible for the proposed trial) * Use of pharmacological immunosuppressive agents within 2 weeks (with the exception of physiologic or stress dose glucocorticoid replacement) or anti-T cell antibodies within 2 months of study participation * Diagnosis of Burkitt lymphoma * Diagnosis of active central nervous system (CNS) leukemia * Known allergy to manufacturing components: human albumin or dimethylsulfoxide (DMSO) * History of HIV infection on anti-retroviral therapy * Positive for hepatitis B or hepatitis C * Active uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved or be improving following optimal therapy * Active autoimmune disease requiring immunosuppressive therapy * Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, or supraventricular tachyarrhythmia requiring chronic therapy) * Females who are pregnant or breastfeeding * Unstable angina, arrhythmias, evidence of acute ischemia or conduction system abnormalities by electrocardiogram (ECG) or myocardial infarction in prior to 2 months * Use of other investigational agents within 2 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Finding of CAR19-tTregs | 28 days after CAR19-tTregs administrations | To identify the MTD of CAR19-tTregs defined asthe dose level that most closely corresponds to a dose limiting toxicity rate(DLT) less than or equal to 25%. Using grade 3-5 Common Terminology Criteria for Adverse Events version 5 (CTCAEv5) Statistical Analysis: The proportion of patients with ORR, CR and adverse events by day 28 will be estimated by simple proportions with 95% confidence intervals |
| Measure CAR19-tTregs efficacy | 28 days after CAR19-tTregs administrations | Efficacy estimate as measured by overall response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of immune cell associated neurotoxicity syndrome (ICANS) | 28 days after CAR19-tTregs administrations | Report the count of neurotoxicities based on the ICANS system. |
| Incidence of relapse in patients achieving complete response (CR) | 1 year after treatment | Report the count of relapses out of those that achieved complete reponse |
| Incidence of CR | 28 days after CAR19-tTregs administrations | Report number patients that achieved complete response (CR) |
| Probability of survival and event free survival | 6 months | The analysis of overall survival will use death as the event, and the analysis of event-free survival will use the earliest of no response, relapse, or death as the event. Patients who do not have an event will have their data censored for the analyses at the date at which they were last known to be alive. Finally, probabilities will be measured using Kaplan-Meier curves |
| Incidence of relapse in patients achieving complete (CR) | Day +100 after treatment | Report the count (as proportions) of relapses out of those that achieved complete re |
| Incidence of grade 3-4 cytokine release syndrome (CRS) | 28 days after CAR19-tTregs administrations | Evaluated using the American Society of Transplantation and Cellular Therapy (ASTCT) CRS consensus grading system |
Countries
United States
Outcome results
None listed